肝硬化合并COVID-19患者30天死亡率高
这项多中心回顾性研究纳入2020年3月1日至31日确诊SARS-CoV-2感染的50例肝硬化患者,评估COVID-19对临床结局的影响。诊断时64%发热、96%需住院或延长住院,71%需呼吸支持;30天死亡率为34%,肺和肝疾病严重程度独立预测死亡。
要点
- 肝硬化合并COVID-19患者30天死亡率为34%,17例死亡中位时间10(4-13)天。
- 诊断时MELD评分≥15者从13%增至26%(p=0.037),28%发生慢加急性肝衰竭。
- 肺和肝疾病严重程度(CLIF-C、CLIF-OF和MELD评分)独立预测死亡。
核心结论
- COVID-19与肝硬化患者肝功能恶化和死亡率升高相关。
研究设计与样本
- 多中心回顾性研究,纳入2020年3月1日至31日确诊SARS-CoV-2感染的50例肝硬化患者(年龄67岁,70%男性,38%病毒相关,52%既往代偿期肝硬化)。
主要发现
- 诊断时64%发热、42%气短/呼吸急促、22%肝性脑病,96%需住院或已住院者需延长住院。
- 71%需呼吸支持,52%接受抗病毒治疗,80%接受肝素治疗。
- 与最近一次可用数据相比,COVID-19诊断时血清白蛋白显著下降,胆红素、肌酐和凝血酶原时间显著升高。
- MELD评分≥15者比例从13%增至26%(p=0.037);14例(28%)发生慢加急性肝衰竭,10例发生新发急性肝损伤。
- 17例死亡,中位时间10(4-13)天,30天死亡率为34%;肺和肝疾病严重程度(CLIF-C、CLIF-OF和MELD评分)独立预测死亡;肝硬化患者中COVID-19者死亡率显著高于因细菌感染住院者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) poses a major health threat to healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is currently unknown. Herein, we aimed to evaluate the impact of COVID-19 on the clinical outcome of patients with cirrhosis. METHODS: In this multicentre retrospective study, patients with cirrhosis and a confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection were enrolled between 1st and 31th March 2020. Clinical and biochemical data at diagnosis of COVID-19 and at the last outpatient visit were obtained through review of medical records. RESULTS: Fifty patients with cirrhosis and confirmed SARS-CoV-2 infection were enrolled (age 67 years, 70% men, 38% virus-related, 52% previously compensated cirrhosis). At diagnosis, 64% of patients presented fever, 42% shortness of breath/polypnea, 22% encephalopathy, 96% needed hospitalization or a prolonged stay if already in hospital. Respiratory support was necessary in 71%, 52% received antivirals, 80% heparin. Serum albumin significantly decreased, while bilirubin, creatinine and prothrombin time significantly increased at COVID-19 diagnosis compared to last available data. The proportion of patients with a model for end-stage liver disease (MELD) score ≥15 increased from 13% to 26% (p = 0.037), acute-on-chronic liver failure and de novo acute liver injury occurred in 14 (28%) and 10 patients, respectively. Seventeen patients died after a median of 10 (4-13) days from COVID-19 diagnosis, with a 30-day-mortality rate of 34%. The severity of lung and liver (according to CLIF-C, CLIF-OF and MELD scores) diseases independently predicted mortality. In patients with cirrhosis, mortality was significantly higher in those with COVID-19 than in those hospitalized for bacterial infections. CONCLUSION: COVID-19 is associated with liver function deterioration and elevated mortality in patients with cirrhosis. LAY SUMMARY: Coronavirus disease 2019 (COVID-19) poses a major health threat to healthy individuals and those with comorbidities. Herein, we assessed its impact on patients with cirrhosis. Infection with COVID-19 was associated with liver function deterioration and elevated mortality in patients with cirrhosis.
引用
- Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020. PMID: 32526252. doi:10.1016/j.jhep.2020.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。